The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation

Introduction In the reason of FDA prohibition in using of "new" oral anticoagulants, vitamin K antagonists have become uncontested drugs to the patients with valvular atrial fibrillation.

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2015-08, Vol.37 (8), p.e24-e24
Main Authors: Shakhidzhanova, V.S, Sychev, D.A, Kazаkov, R.E, Grishenko, N.D, Palamarchuk, Y.Y, Kossovskaya, A.V, Tretyakov, A.Y
Format: Article
Language:English
Subjects:
Anticoagulants
Genotype & phenotype
Internal Medicine
Medical Education
Stroke
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page e24
container_issue 8
container_start_page e24
container_title Clinical therapeutics
container_volume 37
creator Shakhidzhanova, V.S
Sychev, D.A
Kazаkov, R.E
Grishenko, N.D
Palamarchuk, Y.Y
Kossovskaya, A.V
Tretyakov, A.Y
description Introduction In the reason of FDA prohibition in using of "new" oral anticoagulants, vitamin K antagonists have become uncontested drugs to the patients with valvular atrial fibrillation.
doi_str_mv 10.1016/j.clinthera.2015.05.075
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1693848936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0149291815003823</els_id><sourcerecordid>3735347341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2385-1aef9353a7d2a033e6130c00debfd8b8e2da0821a414224ddc65f815e5d03eeb3</originalsourceid><addsrcrecordid>eNqNkV-L1DAUxYsoOK5-BgM-d8yfpk1fhGF03YEFB_ePvoVMcrvNmCY16Sz0A-z3NmVEwSfhQl5-59ybc4riLcFrgkn9_rjWzvqph6jWFBO-xnka_qxYEdG0JSHV9-fFCpOqLWlLxMviVUpHjDFrOV0VT7c9oN0wKj2h0KHtPFYdRfvg5iHEsbdpQMGjBbpRHUwz2sfQWQdo4w36Cg92APQxJOsfFvm-B2-9sVmy82ivJgt-SuibnXp0r9zjyamINlO0yqFLe4jWucwE_7p40SmX4M3v96K4u_x0u70qr7983m0316WmTPCSKOhaxplqDFWYMagJwxpjA4fOiIMAahQWlKiKVJRWxuiad4Jw4AYzgAO7KN6dfccYfp4gTfIYTtHnlZLULROVaFmdqeZM6RhSitDJMdpBxVkSLJfM5VH-yVwumUucp-FZuTkrIX_i0UKUSecINBgbQU_SBPsfHh_-8Vg4q5X7ATOkvwfLRCWWN0uzS7GE504FZewXkHqkiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1693848936</pqid></control><display><type>article</type><title>The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation</title><source>ScienceDirect Journals</source><creator>Shakhidzhanova, V.S ; Sychev, D.A ; Kazаkov, R.E ; Grishenko, N.D ; Palamarchuk, Y.Y ; Kossovskaya, A.V ; Tretyakov, A.Y</creator><creatorcontrib>Shakhidzhanova, V.S ; Sychev, D.A ; Kazаkov, R.E ; Grishenko, N.D ; Palamarchuk, Y.Y ; Kossovskaya, A.V ; Tretyakov, A.Y</creatorcontrib><description>Introduction In the reason of FDA prohibition in using of "new" oral anticoagulants, vitamin K antagonists have become uncontested drugs to the patients with valvular atrial fibrillation.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2015.05.075</identifier><language>eng</language><publisher>Bridgewater: Elsevier Inc</publisher><subject>Anticoagulants ; Genotype &amp; phenotype ; Internal Medicine ; Medical Education ; Stroke</subject><ispartof>Clinical therapeutics, 2015-08, Vol.37 (8), p.e24-e24</ispartof><rights>2015</rights><rights>Copyright Elsevier Limited Aug 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Shakhidzhanova, V.S</creatorcontrib><creatorcontrib>Sychev, D.A</creatorcontrib><creatorcontrib>Kazаkov, R.E</creatorcontrib><creatorcontrib>Grishenko, N.D</creatorcontrib><creatorcontrib>Palamarchuk, Y.Y</creatorcontrib><creatorcontrib>Kossovskaya, A.V</creatorcontrib><creatorcontrib>Tretyakov, A.Y</creatorcontrib><title>The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation</title><title>Clinical therapeutics</title><description>Introduction In the reason of FDA prohibition in using of "new" oral anticoagulants, vitamin K antagonists have become uncontested drugs to the patients with valvular atrial fibrillation.</description><subject>Anticoagulants</subject><subject>Genotype &amp; phenotype</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Stroke</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqNkV-L1DAUxYsoOK5-BgM-d8yfpk1fhGF03YEFB_ePvoVMcrvNmCY16Sz0A-z3NmVEwSfhQl5-59ybc4riLcFrgkn9_rjWzvqph6jWFBO-xnka_qxYEdG0JSHV9-fFCpOqLWlLxMviVUpHjDFrOV0VT7c9oN0wKj2h0KHtPFYdRfvg5iHEsbdpQMGjBbpRHUwz2sfQWQdo4w36Cg92APQxJOsfFvm-B2-9sVmy82ivJgt-SuibnXp0r9zjyamINlO0yqFLe4jWucwE_7p40SmX4M3v96K4u_x0u70qr7983m0316WmTPCSKOhaxplqDFWYMagJwxpjA4fOiIMAahQWlKiKVJRWxuiad4Jw4AYzgAO7KN6dfccYfp4gTfIYTtHnlZLULROVaFmdqeZM6RhSitDJMdpBxVkSLJfM5VH-yVwumUucp-FZuTkrIX_i0UKUSecINBgbQU_SBPsfHh_-8Vg4q5X7ATOkvwfLRCWWN0uzS7GE504FZewXkHqkiA</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Shakhidzhanova, V.S</creator><creator>Sychev, D.A</creator><creator>Kazаkov, R.E</creator><creator>Grishenko, N.D</creator><creator>Palamarchuk, Y.Y</creator><creator>Kossovskaya, A.V</creator><creator>Tretyakov, A.Y</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20150801</creationdate><title>The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation</title><author>Shakhidzhanova, V.S ; Sychev, D.A ; Kazаkov, R.E ; Grishenko, N.D ; Palamarchuk, Y.Y ; Kossovskaya, A.V ; Tretyakov, A.Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2385-1aef9353a7d2a033e6130c00debfd8b8e2da0821a414224ddc65f815e5d03eeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anticoagulants</topic><topic>Genotype &amp; phenotype</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shakhidzhanova, V.S</creatorcontrib><creatorcontrib>Sychev, D.A</creatorcontrib><creatorcontrib>Kazаkov, R.E</creatorcontrib><creatorcontrib>Grishenko, N.D</creatorcontrib><creatorcontrib>Palamarchuk, Y.Y</creatorcontrib><creatorcontrib>Kossovskaya, A.V</creatorcontrib><creatorcontrib>Tretyakov, A.Y</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep (ProQuest)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest_Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shakhidzhanova, V.S</au><au>Sychev, D.A</au><au>Kazаkov, R.E</au><au>Grishenko, N.D</au><au>Palamarchuk, Y.Y</au><au>Kossovskaya, A.V</au><au>Tretyakov, A.Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation</atitle><jtitle>Clinical therapeutics</jtitle><date>2015-08-01</date><risdate>2015</risdate><volume>37</volume><issue>8</issue><spage>e24</spage><epage>e24</epage><pages>e24-e24</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Introduction In the reason of FDA prohibition in using of "new" oral anticoagulants, vitamin K antagonists have become uncontested drugs to the patients with valvular atrial fibrillation.</abstract><cop>Bridgewater</cop><pub>Elsevier Inc</pub><doi>10.1016/j.clinthera.2015.05.075</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-2918
ispartof Clinical therapeutics, 2015-08, Vol.37 (8), p.e24-e24
issn 0149-2918
1879-114X
language eng
recordid cdi_proquest_journals_1693848936
source ScienceDirect Journals
subjects Anticoagulants
Genotype & phenotype
Internal Medicine
Medical Education
Stroke
title The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T07%3A26%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Cyp4f2%20Polymorphism%20on%20The%20Safety%20Profile%20And%20Regime%20Dosing%20of%20Phenindion%20In%20Patients%20With%20Valvular%20Atrial%20Fibrillation&rft.jtitle=Clinical%20therapeutics&rft.au=Shakhidzhanova,%20V.S&rft.date=2015-08-01&rft.volume=37&rft.issue=8&rft.spage=e24&rft.epage=e24&rft.pages=e24-e24&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2015.05.075&rft_dat=%3Cproquest_cross%3E3735347341%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2385-1aef9353a7d2a033e6130c00debfd8b8e2da0821a414224ddc65f815e5d03eeb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1693848936&rft_id=info:pmid/&rfr_iscdi=true